49
3
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T11159 |
EGFR-IN-2
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR-IN-2 is a non-covalent, mutation-selective and irreversible second-generation EGFR inhibitor. | |||
T12130 | Mutated EGFR-IN-2 | EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Mutated EGFR-IN-2 is an inhibitor of mutant-selective EGFR. | |||
T79393 | ALK/EGFR-IN-2 | ||
ALK/EGFR-IN-2 是一种高效的 ALK 和 EGFR 双重抑制剂,能够诱导癌细胞凋亡及 G0/G1 细胞周期停滞。此化合物在 H1975、PC9 和 Baf3-EML4-ALK 癌熙胞株的增殖抑制实验中,其 IC50 值分别为0.0034、0.0065 和 0.0018 μM,表明其对这些癌熙胞系具有显著的抑制作用。 | |||
T79727 |
EGFR/CDK2-IN-2
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR/CDK2-IN-2(compound 6a)是一种针对EGFR和CDK-2的双重抑制剂,具有19.6 nM和87.9 nM的IC50s。该化合物能在MCF-7细胞内诱导凋亡,并在S期引发细胞周期停滞。此外,EGFR/CDK2-IN-2展现出IC50为0.39 μM的显著抗癌活性,对MCF-7细胞具有强效的细胞毒性。 | |||
T78849 |
EGFR/BRAFV600E-IN-2
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
E07 aptamer是靶向人表皮生长因子受体(hEGFR)的适配体,能与EGF竞争性结合至EGFR的新表位。该适配体与表达hEGFR的细胞互作,阻断受体自磷酸化作用,抑制肿瘤细胞在三维基质中的增殖,适用于肿瘤病理研究。 | |||
T62776 |
EGFR/HER2-IN-2
|
||
EGFR/HER2-IN-2 (Compound ZINC35560729) 是一种 EGFR 和 HER2 双重抑制剂,作用于 EGFR (IC50: 5.02 μM) 和 HER2 (IC50: 0.83 μM)。 | |||
T63357 |
EGFR/HER2/CDK9-IN-2
|
||
EGFR/HER2/CDK9-IN-2 是 EGFR/HER2/CDK9 的有效抑制剂,他们的 IC50s 值分别为 145.35、129.07 和 117.13 nM,表现出明显的抗肿瘤作用。 | |||
T74833 | EGFR T790M/L858R-IN-2 | ||
EGFRT790M/L858R-IN-2是一种有效选择性的EGFRT790M/L858R抑制剂,其对EGFRT790M/L858R和EGFRWT的IC50值分别为3.5nM和1290nM。该化合物能够降低p-EGFR、P-AKT、P-ERK1/2的表达,诱导细胞凋亡及细胞周期在G1期的停滞,显示出抗癌活性。 | |||
T63532 |
EGFR/HER2/TS-IN-2
|
||
EGFR/HER2/TS-IN-2 是 EGFR (IC50: 0.173 μM)、HER2 (IC50: 0.125 μM) 和 TS (IC50: 1.12 μM) 的有效抑制剂。EGFR/HER2/TS-IN-2 对 MDA-MB-231 癌细胞表现出细胞毒性作用 (IC50: 1.69 μM)。 | |||
T82493 | EGFR/HER2/DHFR-IN-2 | EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR/HER2/DHFR-IN-2 (Compound 4b) 是针对EGFR、HER2和DHFR的三重抑制剂,IC50分别为0.248、0.156、0.138 μM。该化合物对包括Hep G2, HeLa, HEp-2, HCT 116, PC-3, MCF7在内的多种癌细胞系展现出显著的抗癌活性(IC50分别为9.14、7.33、14.18、24.87、20.07、6.16 μM),并能有效减缓乳腺癌肿瘤的生长。 | |||
T6619 |
Desmethyl Erlotinib hydrochloride
OSI420,OSI-420,DesMethyl Erlotinib (CP-473420) HCl,去甲厄洛替尼,CP-473420,Desmethyl Erlotinib,OSI 420 |
EGFR; Drug Metabolite | Angiogenesis; JAK/STAT signaling; Metabolism; Tyrosine Kinase/Adaptors |
Desmethyl Erlotinib hydrochloride (OSI 420) 是 Erlotinib 的活性代谢物。Erlotinib 是 EGFR 酪氨酸激酶抑制剂。 | |||
T5475 |
ZD-4190
|
EGFR; VEGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
ZD-4190 是血管内皮细胞生长因子受体 2 (VEGFR2) 和表皮生长因子受体 (EGFR) 信号传导的抑制剂,用于治疗癌症。 | |||
T34973 |
Tyrphostin 8
4-Hydroxybenzylidenemalononitrile |
EGFR; GTPase | Angiogenesis; GPCR/G Protein; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Tyrphostin 8(4-Hydroxybenzylidenemalononitrile) 是一种有效的 GTP 酶抑制剂,对 EGFR 激酶有抑制作用, IC50 值为 560 μM。Tyrphostin 8 可抑制蛋白丝氨酸/苏氨酸钙调磷酸酶 (IC50=21 μM),增强 Caco-2 细胞中转铁蛋白受体介导的转吞作用,并增加口服胰岛素 - 转铁蛋白的降血糖作用。 | |||
T16328 |
Nitroaspirin
2-乙酰氧基苯甲酸-3-硝酸甲基苯酯,NCX 4016 |
Apoptosis; COX | Apoptosis; Immunology/Inflammation; Neuroscience |
Nitroaspirin (NCX 4016) 是一氧化氮供体和阿司匹林的硝基衍生物,与 Aspirin 结合可抑制环氧合酶=,可作为 COX-1 的直接和不可逆抑制剂。 它通过下调 EGFR/PI3K/STAT3 信号传导和调节 Bcl-2 家族蛋白,显着诱导顺铂耐药人卵巢癌细胞的细胞周期停滞和凋亡,具有抗血栓和抗血小板特性。 | |||
T2116 |
AEE788
NVP-AEE 788 |
Apoptosis; EGFR; c-Fms; FLT; Bcr-Abl | Angiogenesis; Apoptosis; Cytoskeletal Signaling; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
AEE788 (NVP-AEE 788)是EGFR 和ErbB2的抑制剂,IC50值分别为2和6 nM。它已用于研究癌症、多形性胶质母细胞瘤以及脑和中枢神经系统肿瘤治疗的试验。 | |||
T78940 |
EGFR-IN-78
|
Apoptosis | Apoptosis |
EGFR-IN-78(compound A5)为2-氨基嘧啶衍生物,既是EGFRC797S-TK的可逆抑制剂,也能诱导细胞凋亡(apoptosis)。该化合物展现抗增殖能力,阻止EGFR磷酸化,导致细胞周期在G2/M期暂停。 | |||
T79729 |
EGFR/CDK2-IN-4
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR/CDK2-IN-4(化合物4c)是一种EGFR与CDK-2的双重抑制剂,其IC50值分别为89.6 nM和165.4 nM。该化合物在MCF-7细胞中能诱导(apoptosis)凋亡,并导致细胞周期在S期停滞。EGFR/CDK2-IN-4显示出显著的抗癌细胞毒性,对MCF-7细胞的IC50为2.74 μM。 | |||
T8525 |
EGFR-IN-16
AG473 |
EGFR; FGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR-IN-16 (AG473) 是一种EGFR 抑制剂,对 EGFR 和 HER-2 的pIC50分别为4.85和4.74。 | |||
T11385 |
Gefitinib N-oxide
|
Others | Others |
Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib. | |||
T73627 | Gefitinib N-oxide hydrochloride | ||
Gefitinib N-oxide hydrochloride 是 Gefitinib 的 N-oxide 衍生物。Gefitinib 是一种有效的 (EGFR) 抑制剂,在 NR6wtEGFR 细胞中 IC50值为 2-37 nM。 | |||
T74561 | JBJ-09-063 TFA | ||
JBJ-09-063 TFA 是一种突变选择性变构EGFR 抑制剂,对EGFRL858R、EGFR L858R/T790M、EGFR L858R/T790M/C797S 和 EGFRLT/L747S 的IC50分别为 0.147 nM、0.063 nM、0.083 nM 和 0.396 nM。JBJ-09-063 TFA 有效降低 EGFR、Akt 和 ERK1/2 磷酸化。JBJ-09-063 TFA 对EGFR 酪氨酸激酶抑制剂 (TKI) 敏感和耐药模型均有效。JBJ-09-063 TFA 可用于EGFR 突变型肺癌研究。 | |||
T63769 |
EGFR-IN-60
|
||
EGFR-IN-60 是一种有效的、口服具有活力的、安全的抗肿瘤剂。EGFR-IN-60 能够明显抑制 EGFRWT (IC50: 83 nM)、EGFRT790M (IC50: 26 nM)、EGFRL858R (IC50: 53 nM) 和 JAK3 (IC50: 69 nM)。EGFR-IN-60 能够抑制携带 EGFRT790M 突变的 H1975 细胞 (IC50: 1.32 μM) ,并抑制过表达 EGFRWT 的 A431 细胞 (IC50: 4.96 μM)。EGFR-IN-60 能够提高 Bax/Bcl-2 比率,进而诱导细胞凋亡诱导并导致细胞死亡。 | |||
T61696 | EGFR-IN-57 | ||
EGFR-IN-57 (Compound 25a) 是一种有效的、具有口服活性的EGFR-TK 抑制剂,IC50值为 0.054 μM。EGFR-IN-57 也抑制VEGFR-2、CK2α、topoisomerase IIβ和tubulin polymerization,IC50值分别为 0.087、0.171、0.13 和 3.61 μM。EGFR-IN-57 诱导细胞 G2/M 和 pre-G1 期周期阻滞,诱导癌细胞凋亡 (apoptosis)。 | |||
T63895 | EGFR-IN-62 | ||
EGFR-IN-62 是 EGFR 激酶的有效抑制剂,对 L858R/T790 M、WT 和 L858R/T790 M/C797S 的 IC50 值分别为10 nM、29 nM 和2 42 nM。EGFR-IN-62 可将 A549 和/或 H1975细胞周期阻滞在 G1/G0 期,并诱导凋亡和运动抑制,有效的抑制 A549 细胞 (IC50: 2.53 μM) 和 H1975 细胞 (IC50: 1.56 μM) 的增殖。 | |||
T72237 | JBJ-09-063 hydrochloride | ||
JBJ-09-063 hydrochloride 是一种突变选择性变构EGFR 抑制剂,对EGFRL858R、EGFR L858R/T790M、EGFR L858R/T790M/C797S 和 EGFRLT/L747S 的IC50分别为 0.147 nM、0.063 nM、0.083 nM 和 0.396 nM。JBJ-09-063 hydrochloride 有效降低 EGFR、Akt 和 ERK1/2 磷酸化。JBJ-09-063 hydrochloride 对EGFR 酪氨酸激酶抑制剂 (TKI) 敏感和耐药模型均有效。JBJ-09-063 hydrochloride 可用于EGFR 突变型肺癌研究。 | |||
T35915 |
Erlotinib-13C6
Erlotinib-13C6 |
||
Erlotinib-13C6 (CP-358774-13C6) is a 13C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR[1]. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer[1].Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process[2]... | |||
T77073 | Losatuxizumab | ||
Losatuxizumab (ABT-806) 是一种抗EGFR 单克隆抗体。Losatuxizumab 可结合EGFR,EGFR 野生型 EC50为 0.96 nM,EGFRC271A, C283A 为 0.09 nM,EGFRvIII 为 0.12 nM,EGFR1-501 为 0.66 nM。Losatuxizumab 可用于研究表达EGFR 的癌症。 | |||
T76697 | Panitumumab (anti-EGFR) | ||
Panitumumab (anti-EGFR) 是一种全人源IgG2抗EGFR 单克隆抗体,具有抗肿瘤活性。Panitumumab (anti-EGFR) 抑制肿瘤细胞增殖、存活和血管生成。Panitumumab (anti-EGFR) 可用于癌症研究,例如结肠癌。 | |||
T11384 |
Gefitinib-d8
ZD1839 D8,Gefitinib D8 |
Others | Others |
Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib D8 is a deuterium labeled Gefitinib. | |||
T63939 |
JBJ-09-063
|
||
JBJ-09-063 是一种突变选择性变构 EGFR 抑制剂,对 EGFRL858R、EGFR L858R/T790M、EGFR L858R/T790M/C797S 和 EGFRLT/L747S 的 IC50分别为 0.147 nM、0.063 nM、0.083 nM 和 0.396 nM。JBJ-09-063 有效降低 EGFR、Akt 和 ERK1/2 磷酸化。JBJ-09-063 对EGFR 酪氨酸激酶抑制剂 (TKI) 敏感与耐药模型均有效。JBJ-09-063 可用于EGFR 突变型肺癌研究。 | |||
T1181L |
Gefitinib hydrochloride
|
||
Gefitinib hydrochloride (ZD1839 hydrochloride) 是一种有效,选择性和具有口服活性的EGFR 酪氨酸激酶抑制剂,IC50为 33 nM。Gefitinib hydrochloride 选择性抑制 EGF 刺激的肿瘤细胞生长 (IC50为 54 nM),并阻断 EGF 刺激的肿瘤细胞中EGFR 自磷酸化。Gefitinib hydrochloride 也诱导细胞自噬 (autophagy),具有抗肿瘤活性。 | |||
T74367 |
SC209
|
||
SC209 是个 ADC 细胞毒素, 用于合成抗 EGFR 抗体-活性分子偶联 ADC。SC209 是 STRO-002 的代谢物。 | |||
T79728 |
EGFR/CDK2-IN-3
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR/CDK2-IN-3(compound 4b)是一种针对EGFR与CDK-2的双重抑制剂,分别具有71.7 nM和113.7 nM的IC50s。该化合物在MCF-7细胞中能诱导凋亡,导致细胞周期在S期停滞,并显示出对癌细胞的明显毒性,其对MCF-7细胞的IC50值为3.16 μM。 | |||
T76812 | Intetumumab | ||
Intetumumab (CNTO 95) 是一种有效的抗EGFR 单克隆抗体,是糖工程增强抗体依赖性细胞毒性 (ADCC)。Intetumumab 可用于癌症的研究。 | |||
T69055 |
PD153035 nitrate
|
||
PD153035 is a ATP-competitive EGFR inhibitor with an IC50 and Ki of 25 and 6 pM. PD153035 effectively blocks the enhancement of mitogenesis, induction of early gene expression, and oncogenic transformation that occur in response to EGF receptor stimulation. With human fibroblasts and epidermoid carcinoma cells, PD153035 at nanomolar concentrations rapidly inhibits EGFR autophosphorylation. With breast and ovarian cancer cells, PD153035 not only blocks cell growth via inhibition of EGFR, but also... | |||
T14101 |
Acid-PEG3-C2-Boc
|
Others | Others |
Acid-PEG3-C2-Boc is a compound used as a linker in the synthesis of PROTACs to facilitate the degradation of EGFR and the inhibition of mTOR[1][2]. It is classified as a PEG- and alkyl/ether-based PROTAC linker. | |||
T62621 |
pan-HER-IN-2
|
||
pan-HER-IN-2 (Compound C6) 是一种口服具有活力的、可逆的广谱 HER 抑制剂,能够作用于 EGFR (IC50: 0.72 nM)、HER4 (IC50: 2.0 nM)、EGFRT790M (IC50: 8.2 nM) / L858R (IC50: 75.1 nM)。pan-HER-IN-2 可以诱导细胞凋亡 (apoptosis),具有抗肿瘤作用。 | |||
T36102 |
4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline
|
||
4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline is a building block and synthetic intermediate.1,2,3,4,5It has been used as a precursor in the synthesis of receptor tyrosine kinase (RTK) inhibitors, dual RTK and histone deacetylase (HDAC) inhibitors, and anticancer compounds.1,2,3It is also a synthetic intermediate in the synthesis of EGFR inhibitors, including erlotinib , with antiproliferative activity.4,5 | |||
T72890 | VEGFR-2-IN-30 | ||
VEGFR-2-IN-30为一种针对VEGFR-2的抑制剂(IC50:66 nM),同时对PDGFR、EGFR及FGFR1亦有一定抑制作用,其IC50s分别为180、98、82 nM。此外,VEGFR-2-IN-30能够阻止癌细胞在S期的进展并诱导早期以及晚期的细胞凋亡(apoptosis)。 | |||
T63205 |
HSP90-IN-13
|
||
HSP90-IN-13(compound 5k)是一种有效的HSP90抑制剂,具有25.07 nM的IC50值,并对EGFR、VEGFR-2以及Topoisomerase-2展现出多靶点作用。此外,HSP90-IN-13能够在G2/M期阻滞MCF-7细胞周期,并通过线粒体途径诱导细胞凋亡(apoptosis)。 | |||
T79572 |
MAPK-IN-2
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
MAPK-IN-2 (化合物3h)是一种携带抗肿瘤活性的高效MAPK抑制剂。它在多个癌细胞系中有效抑制了细胞增殖,并对MAPK途径表现出强大的抑制效果(EGFRWT IC50=281 nM, c-MET IC50=205 nM, B-RAFWT IC50=112 nM, CDK4/6 IC50=95和184 nM),对突变型EGFR和B-RAF亦展现出高效力(EGFRT790M IC50=69 nM, B-RAFV600E IC50=83 nM)。 | |||
T35897 |
ASK120067
|
||
ASK120067 is a potent and orally active inhibitor of EGFRT790M (IC50:0.3 nM) with selectivity over EGFRWT (IC50:6.0 nM). ASK120067 is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC)[1]. In the in vitro kinase assay ASK120067 potently inhibits the EGFR L858R/T790M and EGFR T790M resistant mutants with IC50 values of 0.3 nM and 0.5 nM, respectively, as well as the EGFRexon19del sensitizing mutant (IC50= 0.5 nM). The 50 of ASK120067 against wild-type EGFR (EGFRWT... | |||
T35855 |
AAA
|
||
AAA is an antagonist of G protein-coupled receptor 75 (GPR75).1It increases basal GPR75 protein levels and inhibits 20-HETE-induced reductions in GPR75 protein levels in PC3 cells. AAA (5 and 10 μM) also reduces 20-HETE-induced phosphorylation of EGFR, NF-κB, and Akt in, and cell migration of, PC3 cells.In vivo, AAA (10 mg/kg per day) reduces systolic blood pressure, albuminuria, renal angiotensin II levels, and cardiac hypertrophy in a Cyp1a1-Ren-2 transgenic rat model of malignant hypertension... | |||
T79714 |
HDAC3-IN-2
|
HDAC | Chromatin/Epigenetic; DNA Damage/DNA Repair |
HDAC3-IN-2 (compound 4i) 是一种具有纳摩尔级效力的吡嗪酰肼基HDAC3抑制剂,IC50值为14 nM,针对三阴性乳腺癌细胞表现出高效抑制作用。该化合物在细胞内毒性测定中显示,对4T1细胞株的IC50为0.55 μM,对MDA-MB-231细胞株的IC50为0.74 μM。HDAC3-IN-2通过增加乙酰化水平(如H3K9、H3K27和H4K12),促进细胞凋亡(涉及caspase-3、caspase-7和细胞色素c的水平提升),并抑制细胞增殖相关蛋白(如Bcl-2、CD44、EGFR和Ki-67)的表达,从而在荷瘤小鼠模型中表现出显著的体内抗肿瘤作用。 | |||
T81739 | Multi-target kinase inhibitor 2 | EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Multi-target kinase inhibitor 2 (compound 5K) 作为一种multi-targeted kinase抑制剂,对EGFR、Her2、VEGFR2和CDK2酶表现出强效活性,IC50值在40至204 nM之间。此化合物对包括HepG2、HeLa、MDA-MB-231 和 MCF-7在内的多种细胞系均显示出显著的细胞毒性,其IC50值分别为41、57、51 和 59 μM。此外,Multi-target kinase inhibitor 2 还能诱导HepG2细胞发生周期阻滞和凋亡 (apoptosis)。 | |||
T76721 | Zalutumumab | ||
Zalutumumab 是一种高亲和力的纯人类IgG1单克隆抗体,靶向EGFR。Zalutumumab 与表皮生长因子受体的结构域 III 结合,通过阻断表皮生长因子的结合和干扰受体的活性构象发挥作用。Zalutumumab 与IgG 及其 Fab 区段的EC50值分别为 7 和 19 nM。Zalutumumab 可用于癌症的研究。 | |||
T36648 | Tucatinib hemiethanolate | ||
Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM. Tucatinib hemiethanolate has nanomolar activity against purified HER2 enzyme and is approximately 500-fold selective for HER2 versus EGFR in cell-based assays. Tucatinib selectively inhibits the receptor tyrosine kinase HER2 relative to EGFR[1].Tucatinib blocks proliferation and the phosphorylation of HER2 and its downstream effector, Akt in HER2 overexpressing cell lines. In the ... | |||
T37594 |
Pericosine A
|
||
Pericosine A is a fungal metabolite that has been found inP. byssoidesand has anticancer activity.1It inhibits the growth of a variety of cancer cells, including breast, colon, lung, ovary, stomach, and prostate cell lines (GI50s = 0.05-24.55 μM) and increases survival in a P388 mouse xenograft model when administered at a dose of 25 mg/kg. Pericosine A inhibits EGFR by 40 to 70% when used at a concentration of 100 μg/ml. It also reacts with organosulfur compounds in skunk spray to form stable t... | |||
T83911 |
CYY292
|
||
CYY292是一种针对PDGFRα、PDGFRβ、FGFR1、-2和-3的抑制剂(IC50分别为5.35、4.6、28、28和78 nM)。该化合物对这些激酶的选择性高于FGFR4(IC50 > 1,000 nM),但也能抑制c-Kit、VEGFR2、VEGFR1和胰岛素样生长因子1受体(IGF-1R;IC50分别为67、33、36和75 nM),以及EGFR、布鲁顿酪氨酸激酶(BTK)、细胞周期依赖性激酶4(Cdk4)/cyclin D3和MET(IC50分别为128、198、214和396 nM)。CYY292抑制MG-63、U2OS、MNNG/HOS和Saos-2骨肉瘤细胞的增殖(IC50分别为0.84、0.76、1.36和0.72 µM)。在0.3和0.5 µM的浓度下,它抑制U87MG和LN-229胶质母细胞瘤细胞的迁移和侵袭。CYY292(30 mg/kg)在U87MG原位小鼠异种移植模型中降低肿瘤体积并增加生存率。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T4S0544 |
Furanodienone
呋喃二烯酮,莪术呋喃二烯酮 |
Apoptosis; HER | Angiogenesis; Apoptosis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Furanodienone 是来源于姜黄根茎的一种主要生物活性成分,可诱导细胞凋亡。 | |||
T2988 |
(-)-Epigallocatechin Gallate
Epigallocatechol Gallate,(-)-表没食子儿茶素没食子酸酯,EGCG |
Ferroptosis; Reactive Oxygen Species; HIV Protease; Mitochondrial Metabolism; Endogenous Metabolite; Autophagy | Apoptosis; Autophagy; Immunology/Inflammation; Metabolism; Microbiology/Virology; NF-κB; Proteases/Proteasome |
(-)-Epigallocatechin Gallate (EGCG) 是茶类黄酮,具有强大的抗氧化,抗炎和抗癌作用。它可抑制EGFR 信号传导,有抗癌作用。它是谷氨酸脱氢酶 1/2 抑制剂。它通过激活细胞色素c 氧化酶来诱导氧化磷酸化。 | |||
TN5100 | Taspine | ERK; EGFR; BCL; VEGFR; MAPK; Akt | Angiogenesis; Apoptosis; Cytoskeletal Signaling; JAK/STAT signaling; MAPK; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
Taspine shows antitumor activity by modulating the EGFR signaling pathway of Erk1/2 and Akt in vitro and in vivo, it can inhibit growth and induce apoptosis of HUVEC in a dose-dependent manner, it has shown meaningful angiogenesis activity. Taspine exhibi |